Analyzing...
Loading company...
Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. The company is headquartered in Gurgaon, Haryana and currently employs 4,048 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.
No significant concerns identified
Nothing flagged for monitoring
“Services business in Healthcare — Hospitals & Diagnostics.”
₹2,763 Cr service revenue.
Employee costs at 18.2% of revenue — primary cost driver.
“year on year growth of 10.”
“We are confident that we should be able to deliver between 11% to 12% organic growth for the year.”
“INR $6.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 20.1%▲ | 9.0% |
| ROCE | 25.7%▲ | 10.4% |
| Net Margin | 17.6%▲ | 8.5% |
| EBITDA Margin | 29.8%▲ | 20.6% |
| Debt To Equity | 0.00x▼ | 0.16x |
| Rev Growth 3yr | 11.6%▼ | 14.4% |
| EPS Growth 3yr | 28.1%▲ | 9.9% |
| Employee Cost Ratio | 18.20x | - |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,891 Cr +17.4% | ₹2,461 Cr +10.5% | ₹2,227 Cr +10.4% | ₹2,017 Cr -3.4% | ₹2,087 Cr +32.0% | ₹1,581 Cr +18.9% | ₹1,330 Cr +10.6% | ₹1,203 Cr |
| Other Income | ₹105 Cr +12.5% | ₹93 Cr +35.0% | ₹69 Cr +65.9% | ₹42 Cr -20.6% | ₹53 Cr +2.3% | ₹51 Cr -6.7% | ₹55 Cr +19.6% | ₹46 Cr |
| Total Income | ₹2,996 Cr +17.3% | ₹2,555 Cr +11.3% | ₹2,296 Cr +11.5% | ₹2,059 Cr -3.8% | ₹2,140 Cr +31.1% | ₹1,633 Cr +17.8% | ₹1,385 Cr +10.9% | ₹1,249 Cr |
| COGS | ₹557 Cr +15.8% | ₹482 Cr +6.7% | ₹451 Cr +0.9% | ₹447 Cr -11.0% | ₹502 Cr +26.4% | ₹397 Cr +33.0% | ₹299 Cr +13.8% | ₹262 Cr |
| ₹2,249 Cr +16.5% | ₹1,930 Cr +7.8% | ₹1,790 Cr +4.4% | ₹1,715 Cr +3.0% | ₹1,665 Cr +34.5% | ₹1,238 Cr +15.2% | ₹1,075 Cr +13.3% | ₹949 Cr | |
| Profit Before Tax | ₹717 Cr +14.7% | ₹625 Cr +23.6% | ₹506 Cr +47.0% | ₹344 Cr -27.6% | ₹475 Cr +20.4% | ₹394 Cr +27.0% | ₹311 Cr +3.3% | ₹301 Cr |
| Exceptional Items | (₹30 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹170 Cr +28.6% | ₹133 Cr -7.5% | ₹143 Cr +39.3% | ₹103 Cr -17.5% | ₹125 Cr +27.3% | ₹98 Cr +18.1% | ₹83 Cr -17.2% | ₹100 Cr | |
| Net Profit | ₹546 Cr +11.0% | ₹492 Cr +35.9% | ₹362 Cr +50.3% | ₹241 Cr -31.2% | ₹350 Cr +18.1% | ₹297 Cr +30.3% | ₹228 Cr +13.5% | ₹201 Cr |
| Profit (Owners) | ₹542 Cr +11.3% | ₹487 Cr +36.2% | ₹358 Cr +49.7% | ₹239 Cr -30.7% | ₹345 Cr +18.2% | ₹292 Cr +29.1% | ₹226 Cr +13.4% | ₹199 Cr |
| Minority Interest | ₹4 Cr -13.7% | ₹5 Cr +10.9% | ₹5 Cr +109.1% | ₹2 Cr -60.0% | ₹6 Cr +12.2% | ₹5 Cr +188.2% | ₹2 Cr +30.8% | ₹1 Cr |
| Other Comprehensive Income | ₹8 Cr ↑ Recovery | (₹4 Cr) -500.0% | (₹0.60 Cr) ↓ Decline | ₹2 Cr ↑ Recovery | (₹1 Cr) -62.5% | (₹0.80 Cr) +27.3% | (₹1 Cr) +45.0% | (₹2 Cr) |
| EPS | ₹32.35 | ₹29.14 | ₹21.42 | ₹14.33 | ₹20.69 | ₹17.49 | ₹13.55 | ₹11.95 |
| Diluted Shares | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Change in Director(s) of the company.
Dr. Lal Path Labs Ltd. has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 25, 2026. Further, the company has informed the Exchange regarding voting results.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Proceedings of Annual General Meeting held on July 25, 2026
Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication
Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated July 24, 2026, titled "Press Release on Un-audited Financial Results (Standalone and Consolidated) for the Quarter ende...
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Grant of 119300 Stock Options.
Dr. Lal Path Labs Ltd. has informed the Exchange about Acquisition(s) :1. Took note that the Board of Dr Lal PathLabs FZCO, Dubai, Wholly Owned Subsidiary of the Company, approved acquisition of stake...
Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of Dividend is 30-Jul-2026.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on July 24, 2026.
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on July 24, 2026, declared Interim Dividend of Rs. 5 per equity share.
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates - Received an appellant order from Income Tax Department
Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet